Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Eurofins Optimed | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
This is a phase 3, multicentre, prospective, single-blind on principal efficacy criterion, 2 parallel groups, randomized, controlled clinical study comparing efficacy and safety of actiTENS versus systemic level 2 analgesics recommended for the treatment of moderate or severe, nociceptive, chronic pain in patients suffering from osteoarthritis of the knee.
Osteoarthritis (OA) is a debilitating chronic condition requiring long-term treatment of pain and inducing functional impairment. More specifically knee osteoarthritis (KOA) is a common disease associated with significant morbidity. Its prevalence increases with age dramatically. KOA is frequently associated with pain which can worsen with daily activities. The goals of KOA treatments are to provide pain relief and to improve function and quality of life. For the American college of Rheumatology and despite the frequent use of TENS in treating patients with KOA, questions remained regarding its efficacy. Consequently TENS needs additional clinical studies to demonstrate its efficacy in management of painful osteoarthritis.
The main objective of this study is to demonstrate the efficacy and to the safety of TENS in the management of chronic, nociceptive pain in patient suffering from KOA.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TENS | Experimental | Treatment by non-pharmacological transcutaneous electric nerve stimulation (TENS) |
|
| level 2 systemic analgesic treatments | Active Comparator | Treatment by level 2 analgesic pharmacological treatment indicated in the treatment of chronic nociceptive pain of moderate to severe intensity. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ActiTENS | Device | ActiTENS is a rechargeable box, weighing 64g attached by Velcro to an adhesive support, which can be positioned on the skin at any position chosen by the patient. The patient will use the programme (P4) prescribed by his doctor and will regulate the intensity of stimulation using an application downloaded to his smartphone which will communicate with the box via Bluetooth. |
| Measure | Description | Time Frame |
|---|---|---|
| Efficacy : pain intensity evaluated by a numerus scale from 0 to 10 | Pain intensity (PI) at M3 between both treatment groups. Numerus scale with a minimum of 0 (no pain) to a maximum of 10 (maximum pain). | 3 months after dosing |
| Safety : occurence of adverse events | Number of adverse events (AE) occurred during the 3 months of follow-up and due to studied treatments. | 3 months after dosing |
| Measure | Description | Time Frame |
|---|---|---|
| Efficacy : pain intensity evaluated by a numerus scale from 0 to 10 | Minimum, maximum,median and difference of pain intensity (PI) during movement and at rest at M1, M3 and M6 between both treatment groups | 1, 3 and 6 months after dosing |
| Efficacy : functional status evaluated by the WOMAC score (Western Onatario McMaster score) |
Not provided
Inclusion Criteria:
Adult > or = 55 years.
Being monitored by a rheumatologist in private practice or in a hospital.
Presenting nociceptive pain:
Of moderate to severe intensity equal to or above 4 on a numerical scale of 0-10.
In a situation of analgesic therapy failure for level 1 analgesics:
Requiring a level 2 prescription.
Affiliated to social security insurance.
Informed of the concept and agreeing to use the TENS as a non-medicinal analgesic treatment.
Capable of understanding how to use the TENS and the level 2 analgesic treatments.
Intellectually and physically able to participate in the study in the opinion of the investigator.
Owns a Smartphone to be able to download the actiTENS application.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Patricia Abraham Briffod | Contact | +33 4 76 37 17 58 | contact@subli-med.com |
| Name | Affiliation | Role |
|---|---|---|
| Bernard CORTET, Pr | Hôpital Roger Salengro - Service de Rhumatologie | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpital Roger Salengro | Recruiting | Lille | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35069809 | Derived | Maheu E, Soriot-Thomas S, Noel E, Ganry H, Lespessailles E, Cortet B. Wearable transcutaneous electrical nerve stimulation (actiTENS(R)) is effective and safe for the treatment of knee osteoarthritis pain: a randomized controlled trial versus weak opioids. Ther Adv Musculoskelet Dis. 2022 Jan 18;14:1759720X211066233. doi: 10.1177/1759720X211066233. eCollection 2022. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020370 | Osteoarthritis, Knee |
| D010146 | Pain |
| D059226 | Nociceptive Pain |
| ID | Term |
|---|---|
| D010003 | Osteoarthritis |
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Level 2 Analgesic Treatments | Drug | There are 4 level 2 oral analgesic treatments indicated for chronic nociceptive pain of moderate to severe intensity (between 4 and 7 on a simple numerical scale of 11 points) (12):
|
|
Functional status (pain, function, stiffness) at M1, M3 and M6. |
| 1, 3 and 6 months after dosing |
| Efficacy : pain relief (PAR) evaluated by the pain visual analogue scale (VAS) | Pain relief at M1, M3 and M6. VAS from 0 to 10 with 0 = no relief and 10 = total relief). Scale of 100 mm. | 1, 3 and 6 months after dosing |
| Efficacy : quality of life evaluated by the questionnaire EuroQol-5D | Evaluation of the quality of life at M1, M3 and M6 | 1, 3 and 6 months after dosing |
| Efficacy : patient global impression of change evaluated by a global impression questionnaire. | Evaluation of the change on activity, symptoms, emotions, quality of life regarding the pain of patient at M1, M3 and M6 | 1, 3 and 6 months after dosing |
| Efficacy : drop-outs for inefficacy | Evaluation of the number of patient drop outs because of treatment inefficacy in each arm | Through study completion, an average of 6 months |
| Efficacy : prolongation of studied treatment | Evaluation of the number of patient wishes to continue the studied treatment. | Through study completion, an average of 6 months |
| Safety : occurrence of Adverse Events (AE) | Evaluation by the type of AE and the date of occurence | Through study completion, an average of 6 months |
| Safety : drop-outs for AE and corrective treatments | Evaluation of the number of patient drop outs because of the occurence of adverse events in each arm | Through study completion, an average of 6 months |
| Estimation of direct costs. | Comparison of treatment costs between the two arms | Through study completion, an average of 6 months |
| D012216 |
| Rheumatic Diseases |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |